Doubt over omega-3 supplements for cardiac protection
Flying in the face of earlier research, a new study finds no support for the concept that supplementation with high-dose omega-3 fatty acids reduces cardiovascular events in patients at high risk.
In the study, a secondary analysis of the STRENGTH trial, patients who achieved the highest levels of eicosapentaenoic acid (EPA) – a 443% increase over baseline – had similar rates of major adverse cardiovascular events as their peers taking a placebo.